Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.

Development, validation and application of a novel HPLC-MS/MS method for the quantification of atorvastatin, bisoprolol and clopidogrel in a large cardiovascular patient cohort.

Turner RM, Fontana V, Bayliss M, Whalley S, Santoyo Castelazo A, Pirmohamed M.

J Pharm Biomed Anal. 2018 Sep 10;159:272-281. doi: 10.1016/j.jpba.2018.06.062. Epub 2018 Jul 3.

2.

Decoding resistant hypertension signalling pathways.

Parreira RC, Lacerda LHG, Vasconcellos R, Lima SS, Santos AK, Fontana V, Sandrim VC, Resende RR.

Clin Sci (Lond). 2017 Nov 28;131(23):2813-2834. doi: 10.1042/CS20171398. Print 2017 Dec 1. Review.

PMID:
29184046
3.

Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery.

Linciano P, Dawson A, Pöhner I, Costa DM, Sá MS, Cordeiro-da-Silva A, Luciani R, Gul S, Witt G, Ellinger B, Kuzikov M, Gribbon P, Reinshagen J, Wolf M, Behrens B, Hannaert V, Michels PAM, Nerini E, Pozzi C, di Pisa F, Landi G, Santarem N, Ferrari S, Saxena P, Lazzari S, Cannazza G, Freitas-Junior LH, Moraes CB, Pascoalino BS, Alcântara LM, Bertolacini CP, Fontana V, Wittig U, Müller W, Wade RC, Hunter WN, Mangani S, Costantino L, Costi MP.

ACS Omega. 2017 Sep 30;2(9):5666-5683. doi: 10.1021/acsomega.7b00473. Epub 2017 Sep 11.

4.

Matrix metalloproteinase-2 -735C/T polymorphism is associated with resistant hypertension in a specialized outpatient clinic in Brazil.

Sabbatini AR, Barbaro NR, de Faria AP, Ritter AMV, Modolo R, Correa NB, Brunelli V, Pinho C, Fontana V, Moreno H.

Gene. 2017 Jul 15;620:23-29. doi: 10.1016/j.gene.2017.04.004. Epub 2017 Apr 5.

PMID:
28390988
5.

Chroman-4-One Derivatives Targeting Pteridine Reductase 1 and Showing Anti-Parasitic Activity.

Di Pisa F, Landi G, Dello Iacono L, Pozzi C, Borsari C, Ferrari S, Santucci M, Santarem N, Cordeiro-da-Silva A, Moraes CB, Alcantara LM, Fontana V, Freitas-Junior LH, Gul S, Kuzikov M, Behrens B, Pöhner I, Wade RC, Costi MP, Mangani S.

Molecules. 2017 Mar 8;22(3). pii: E426. doi: 10.3390/molecules22030426.

6.

Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.

Borsari C, Santarem N, Torrado J, Olías AI, Corral MJ, Baptista C, Gul S, Wolf M, Kuzikov M, Ellinger B, Witt G, Gribbon P, Reinshagen J, Linciano P, Tait A, Costantino L, Freitas-Junior LH, Moraes CB, Bruno Dos Santos P, Alcântara LM, Franco CH, Bertolacini CD, Fontana V, Tejera Nevado P, Clos J, Alunda JM, Cordeiro-da-Silva A, Ferrari S, Costi MP.

Eur J Med Chem. 2017 Jan 27;126:1129-1135. doi: 10.1016/j.ejmech.2016.12.017. Epub 2016 Dec 9.

PMID:
28064141
7.

Gene-Gene Interactions Among PRKCA, NOS3 and BDKRB2 Polymorphisms Affect the Antihypertensive Effects of Enalapril.

Oliveira-Paula GH, Luizon MR, Lacchini R, Fontana V, Silva PS, Biagi C, Tanus-Santos JE.

Basic Clin Pharmacol Toxicol. 2017 Mar;120(3):284-291. doi: 10.1111/bcpt.12682. Epub 2016 Dec 20.

8.

Increased Circulating Tissue Inhibitor of Metalloproteinase-2 Is Associated With Resistant Hypertension.

Sabbatini AR, Barbaro NR, de Faria AP, Modolo R, Ritter AM, Pinho C, Amorim RF, Fontana V, Moreno H.

J Clin Hypertens (Greenwich). 2016 Oct;18(10):969-975. doi: 10.1111/jch.12865. Epub 2016 Jul 14.

9.

Endothelial nitric oxide synthase tagSNPs influence the effects of enalapril in essential hypertension.

Oliveira-Paula GH, Lacchini R, Luizon MR, Fontana V, Silva PS, Biagi C, Tanus-Santos JE.

Nitric Oxide. 2016 May 1;55-56:62-9. doi: 10.1016/j.niox.2016.03.006. Epub 2016 Apr 6.

PMID:
27060232
10.

Vascular Damage in Resistant Hypertension: TNF-Alpha Inhibition Effects on Endothelial Cells.

Barbaro NR, de Araújo TM, Tanus-Santos JE, Anhê GF, Fontana V, Moreno H.

Biomed Res Int. 2015;2015:631594. doi: 10.1155/2015/631594. Epub 2015 Oct 4.

11.

Does Renal Denervation Fit All Resistant Hypertension? The Role of Genetics.

Ritter AM, de Faria AP, Fontana V, Modolo R, Moreno H.

J Clin Hypertens (Greenwich). 2016 Feb;18(2):161-2. doi: 10.1111/jch.12642. Epub 2015 Aug 3. No abstract available.

12.

Association of Mineralocorticoid Receptor Polymorphism I180V With Left Ventricular Hypertrophy in Resistant Hypertension.

Ritter AM, Fontana V, Faria AP, Modolo R, Barbaro NR, Sabbatini AR, Peres H, Biagi C, Silva PS, Lopes PC, Tanus-Santos JE, Coelho EB, Moreno H.

Am J Hypertens. 2016 Feb;29(2):245-50. doi: 10.1093/ajh/hpv070. Epub 2015 Jun 6.

PMID:
26049084
13.

Role of MMP-2 and MMP-9 in resistance to drug therapy in patients with resistant hypertension.

Lacerda L, Faria AP, Fontana V, Moreno H, Sandrim V.

Arq Bras Cardiol. 2015 Aug;105(2):168-75. doi: 10.5935/abc.20150060. Epub 2015 Jun 2. English, Portuguese.

14.

Adiponectin -11377C/G and +276G/T polymorphisms affect adiponectin levels but do not modify responsiveness to therapy in resistant hypertension.

de Faria AP, Modolo R, Sabbatini AR, Barbaro NR, Corrêa NB, Brunelli V, Tanus-Santos JE, Fontana V, Moreno H.

Basic Clin Pharmacol Toxicol. 2015 Jul;117(1):65-72. doi: 10.1111/bcpt.12368. Epub 2015 Jan 14.

15.

An update on the role of adipokines in arterial stiffness and hypertension.

Sabbatini AR, Fontana V, Laurent S, Moreno H.

J Hypertens. 2015 Mar;33(3):435-44. doi: 10.1097/HJH.0000000000000444. Review.

PMID:
25502905
16.

Large-scale gene-centric analysis identifies polymorphisms for resistant hypertension.

Fontana V, McDonough CW, Gong Y, El Rouby NM, Sá AC, Taylor KD, Chen YD, Gums JG, Chapman AB, Turner ST, Pepine CJ, Johnson JA, Cooper-DeHoff RM.

J Am Heart Assoc. 2014 Nov 10;3(6):e001398. doi: 10.1161/JAHA.114.001398.

17.

DC isoketal-modified proteins activate T cells and promote hypertension.

Kirabo A, Fontana V, de Faria AP, Loperena R, Galindo CL, Wu J, Bikineyeva AT, Dikalov S, Xiao L, Chen W, Saleh MA, Trott DW, Itani HA, Vinh A, Amarnath V, Amarnath K, Guzik TJ, Bernstein KE, Shen XZ, Shyr Y, Chen SC, Mernaugh RL, Laffer CL, Elijovich F, Davies SS, Moreno H, Madhur MS, Roberts J 2nd, Harrison DG.

J Clin Invest. 2014 Oct;124(10):4642-56. doi: 10.1172/JCI74084. Epub 2014 Sep 17.

18.

Adipokines: novel players in resistant hypertension.

de Faria AP, Modolo R, Fontana V, Moreno H.

J Clin Hypertens (Greenwich). 2014 Oct;16(10):754-9. doi: 10.1111/jch.12399. Epub 2014 Sep 4. Review.

19.

Predictors of silent myocardial ischemia in resistant hypertensive patients.

Modolo R, de Faria AP, Paganelli MO, Sabbatini AR, Barbaro NR, Nascimento BB, Ramos CD, Fontana V, Calhoun DA, Moreno H.

Am J Hypertens. 2015 Feb;28(2):200-7. doi: 10.1093/ajh/hpu140. Epub 2014 Jul 25.

PMID:
25063735
20.

Increased arterial stiffness in resistant hypertension is associated with inflammatory biomarkers.

Barbaro NR, Fontana V, Modolo R, De Faria AP, Sabbatini AR, Fonseca FH, Anhê GF, Moreno H.

Blood Press. 2015 Feb;24(1):7-13. doi: 10.3109/08037051.2014.940710. Epub 2014 Jul 25.

PMID:
25061978

Supplemental Content

Loading ...
Support Center